Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial

Azzouzi, Abdel Rahmène; Vincendeau, S.; Barret, Éric; Cicco, Antony; Kleinclauss, F.; Poel, Henk G. van der; Stief, Christian G.; Rassweiler, Jens; Salomon, Georg; Solsona, E.; Alcaraz, Antonio; Tammela, Teuvo; Rosario, Derek J.; Gómez-Veiga, F.; Ahlgren, Göran; Benzaghou, Fawzi; Gaillac, B.; Amzal, Billy; Debruyne, F.M.J.; Fromont, Gaëlle; Gratzke, Christian; Emberton, Mark

doi:10.1016/s1470-2045(16)30661-1

Cited by 290 publications

(221 citation statements)

References 21 publications

Supporting

Mentioning

211

Contrasting

Unclassified

Order By: Relevance

“…retained in the blood vessels (Krzykawska-Serda et al, 2014;Azzouzi et al, 2017). The short drug (PS administration)-tolight (illumination) interval (DLI) and non-specific accumulation of PS would definitely limit the application of passive PS-delivery-based vascular-targeted PDT in the clinic.…”

Section: Discussionmentioning

confidence: 99%

PDGFRβ-specific affibody-directed delivery of a photosensitizer, IR700, is efficient for vascular-targeted photodynamic therapy of colorectal cancer

et al. 2017

View full text Add to dashboard Cite

Lu (2017) PDGFRβ-specific affibody-directed delivery of a photosensitizer, IR700, is efficient for vascular-targeted photodynamic therapy of colorectal cancer, Drug Delivery, 24:1, 1818-1830, DOI: 10.1080/10717544.2017 Conventional vascular-targeted PDT has been achieved by passive photosensitizer (PS) delivery, which involves a high risk of adverse effects. Active PS delivery is urgently required for vascular-targeted PDT. Although endothelial cells and pericytes are major cellular components of tumor blood vessels, little attention has been paid to pericyte-targeted PDT for cancer therapy. PDGFRb is abundantly expressed in the pericytes of various tumors. In this experiment, a dimeric Z PDGFRb affibody with a 0.9 nM affinity for PDGFRb was produced. The Z PDGFRb affibody showed PDGFRb-dependent pericyte binding. Intravenously injected Z PDGFRb affibody was predominantly distributed on pericytes and thus accumulated in LS174T tumor grafts. The conjugate of the Z PDGFRb affibody and IR700 dye, i.e. Z IR700 , bound to PDGFRb þ pericytes but not to PDGFRb À LS174T tumor cells. Accordingly, Z IR700 -mediated PDT in vitro induced the death of pericytes but not of LS174T tumor cells. In mice bearing LS174T tumor grafts, Z IR700 -mediated PDT damaged tumor blood vessels, thus inducing tumor destruction by intensifying tissue hypoxia. The average mass of tumor grafts administered with Z IR700 -mediated PDT was approximately 20-30% of that of the control, indicating that pericyte-targeted PDT is efficient for cancer therapy. In addition, Z IR700 -mediated PDT increased the tumor uptake of TNF-related apoptosis-inducing ligand (TRAIL) injected post-illumination. Consequently, combination therapy of Z IR700 -mediated PDT and TRAIL showed greater tumor suppression than Z IR700 -mediated PDT-or TRAIL-based monotherapy. These results demonstrated that active vascular-targeted PDT could be achieved by using Z PDGFRb affibody-directed delivery of PS. ARTICLE HISTORY

show abstract

Section: Discussionmentioning

confidence: 99%

PDGFRβ-specific affibody-directed delivery of a photosensitizer, IR700, is efficient for vascular-targeted photodynamic therapy of colorectal cancer

et al. 2017

View full text Add to dashboard Cite

show abstract

“…After two years of follow-up, a higher proportion of men treated with photodynamic therapy had a negative biopsy result than in the active surveillance group (49% v 14%, P<0.0001). 7 Although these results favour targeted photodynamic therapy, they do not provide unequivocal support for its preferential use in men with low risk prostate cancer.…”

mentioning

confidence: 95%

“…7 Progression was defined as advances in the extent, grade, or stage of disease, increase in PSA concentration, or cancer related death. After two years of follow-up, a higher proportion of men treated with photodynamic therapy had a negative biopsy result than in the active surveillance group (49% v 14%, P<0.0001).…”

mentioning

confidence: 99%

“…In comparison, many case series report a 25-35% progression rate during active surveillance and 67% with detectable cancer at two years. [4][5][6][7][8] The relatively high proportion of participants who had grade progression during active surveillance (44%) suggests that the entire study population may not have been truly low risk. In "real world" case series grade progression during active surveillance is 10-30%.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Photodynamic therapy for low risk prostate cancer

Ritch

Punnen

2017

BMJ

View full text Add to dashboard Cite

show abstract

“…14,15 In the current study we set out to determine the long-term outcomes and histologic changes after WST-D/NIR treatment in an in vivo rabbit model, to evaluate the validity of this novel treatment for corneal CXL in a clinical setting.…”

mentioning

confidence: 99%

Long-Term Biomechanical and Histologic Results of WST-D/NIR Corneal Stiffening in Rabbits, Up to 8 Months Follow-up

Brekelmans

Goz

Dickman

et al. 2017

Invest. Ophthalmol. Vis. Sci.

View full text Add to dashboard Cite

Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial

Abstract: Steba Biotech.

Cited by 290 publications

References 21 publications

PDGFRβ-specific affibody-directed delivery of a photosensitizer, IR700, is efficient for vascular-targeted photodynamic therapy of colorectal cancer

PDGFRβ-specific affibody-directed delivery of a photosensitizer, IR700, is efficient for vascular-targeted photodynamic therapy of colorectal cancer

Photodynamic therapy for low risk prostate cancer

Long-Term Biomechanical and Histologic Results of WST-D/NIR Corneal Stiffening in Rabbits, Up to 8 Months Follow-up

Contact Info

Product

Resources

About